Unravelling the Mystery of Long COVID: HIQA Reviews Potential Interventions

By HEOR Staff Writer

July 31, 2023

HIQA continues to lead the charge in understanding and managing Long COVID. Their latest systematic review explores potential interventions aimed at improving the varied and often debilitating symptoms of this complex condition. While no definitive treatments have been identified yet, their research continue.

The review included 57 randomised controlled trials of interventions for adults with Long COVID symptoms, typically in people with less than a year’s duration and no pre-existing chronic illnesses. The studies varied in intervention type and were generally short-term, with small sample sizes and not enough focus on specific subpopulations like older adults or those with chronic conditions. There was also insufficient examination of intervention safety. The interventions proposed in this review for Long COVID symptoms lack sufficient evidence for their effectiveness. Personalised exercise and physiotherapy involving breathing exercises may have short-term benefits, but their long-term effects were not assessed. More research is needed to investigate the effectiveness and safety of other treatments, and a greater understanding of Long COVID’s pathophysiology could help design targeted interventions. In the absence of strong evidence, a holistic approach is recommended to support those living with Long COVID.

Reference url

Recent Posts

Dutch Medicine Access Delay
Dutch Medicine Access Delay Impact on Patient Care in the Netherlands

By João L. Carapinha

June 10, 2026

Dutch Medicine Access Delay leaves patients in the Netherlands waiting far longer for innovative drugs than those in Germany. Of 51 treatments currently held in the Dutch assessment pathway, 48 are already on the market across the border, revealing a persistent structural lag driven by mandatory ...
Factor XIa Inhibition Stroke
Advancements in Factor XIa Inhibition Stroke Prevention Through Asundexian

By HEOR Staff Writer

June 10, 2026

The European Medicines Agency has accepted Bayer’s marketing authorization application for asundexian, marking a major advance in Factor XIa Inhibition Stroke prevention. This oral agent selectively interrupts a key step in the coagulation cascade to reduce recurrent ischemic stroke risk in adult...
Federated Generative Learning
Advancing Medical AI through Federated Generative Learning

By HEOR Staff Writer

June 10, 2026

Federated Generative Learning is emerging as a practical breakthrough for multi-center medical image analysis, simultaneously tackling communication overhead, data scarcity, and institutional heterogeneity. The framework trains a shared prompt generator that produces individualized visual prompts...